Trial Profile
A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Various Dosing Regimens of Intravenous anti-Hendra Virus Antibody (mAb m102.4) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2020
Price :
$35
*
At a glance
- Drugs M 102.4 (Primary)
- Indications Nipah virus infections; Viral infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- 30 Nov 2016 Status changed from recruiting to completed.
- 30 Oct 2015 New trial record